General Surgery, First Affiliated Hospital of Soochow University, Suzhou, China.
Oncology, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Postgrad Med J. 2020 May;96(1135):286-295. doi: 10.1136/postgradmedj-2019-137172. Epub 2020 Feb 13.
The prognostic value of long intergenic non-protein coding RNA 460 (LINC00460) overexpression in human solid malignant tumours remains unclear. Therefore, we conducted the meta-analysis to systematically review and assess the evidence for the correlation between LINC00460 overexpression and clinicopathological features and overall survival (OS) of patients with solid malignant tumour. An electronic search of PubMed, EMBASE, Web of Science, CNKI, Cochrane Library, Chinese Biological Medical Literature database and WanFang database was applied to select eligible articles. Pooled ORs or HRs with their 95% CIs were calculated to estimate the effects. 9 eligible studies with a total of 935 patients were enrolled in this meta-analysis. The results revealed that high LINC00460 expression was associated with positive lymph node metastasis (positive vs negative: OR=2.97, 95% CI 1.74 to 5.05, p=0.812), advanced tumour-node-metastasis stage (III+IV vs I+II: OR=2.82, 95% CI 1.64 to 4.85, p=0.193) and poorer differentiation (high vs low: OR=0.60, 95% CI 0.36 to 0.99, p=0.569). Additionally, the overexpression of LINC00460 could predict a poorer OS (HR=1.57, 95% CI 1.39 to 1.77) and the shorter disease-free survival (HR=2.32, 95% CI 1.25 to 4.31). Furthermore, according to subgroup analysis and meta-regression results, the heterogeneity of current meta-analysis may be attributed to the differences of cancer type and follow-up months. High expression of LINC00460 could predict poor prognosis in patients with solid malignant tumour. LINC00460 may serve as potential prognostic biomarker for clinical outcomes in various human solid malignant tumours.
长链非编码 RNA 460（LINC00460）过表达对人类实体恶性肿瘤的预后价值尚不清楚。因此，我们进行了荟萃分析，以系统地回顾和评估 LINC00460 过表达与实体恶性肿瘤患者临床病理特征和总生存期（OS）之间相关性的证据。应用电子搜索 PubMed、EMBASE、Web of Science、CNKI、Cochrane 图书馆、中国生物医学文献数据库和万方数据库，以选择合格的文章。使用合并 OR 或 HR 及其 95%CI 来评估效果。这项荟萃分析共纳入 9 项合格的研究，共 935 例患者。结果表明，LINC00460 高表达与阳性淋巴结转移（阳性与阴性：OR=2.97，95%CI 1.74 至 5.05，p=0.812）、晚期肿瘤-淋巴结-转移分期（III+IV 与 I+II：OR=2.82，95%CI 1.64 至 4.85，p=0.193）和较差的分化（高与低：OR=0.60，95%CI 0.36 至 0.99，p=0.569）有关。此外，LINC00460 的过表达可预测较差的 OS（HR=1.57，95%CI 1.39 至 1.77）和较短的无病生存期（HR=2.32，95%CI 1.25 至 4.31）。此外，根据亚组分析和荟萃回归结果，当前荟萃分析的异质性可能归因于癌症类型和随访月份的差异。LINC00460 的高表达可预测实体恶性肿瘤患者的不良预后。LINC00460 可能成为各种人类实体恶性肿瘤临床结局的潜在预后生物标志物。
